Annual Shareholders Equity
$245.91 M
+$322.73 M+420.09%
December 31, 2023
Summary
- As of February 7, 2025, ELVN annual stockholders equity is $245.91 million, with the most recent change of +$322.73 million (+420.09%) on December 31, 2023.
- During the last 3 years, ELVN annual shareholders equity has risen by +$266.21 million (+1311.12%).
- ELVN annual shareholders equity is now at all-time high.
Performance
ELVN Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Shareholders Equity
$288.40 M
-$16.53 M-5.42%
September 30, 2024
Summary
- As of February 7, 2025, ELVN quarterly stockholders equity is $288.40 million, with the most recent change of -$16.53 million (-5.42%) on September 30, 2024.
- Over the past year, ELVN quarterly shareholders equity has dropped by -$29.31 million (-9.23%).
- ELVN quarterly shareholders equity is now -9.23% below its all-time high of $317.71 million, reached on March 31, 2024.
Performance
ELVN Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Shareholders Equity Formula
Shareholders Equity = Total Assets − Total Liabilities
ELVN Shareholders Equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +420.1% | -9.2% |
| 3 y3 years | +1311.1% | -1.0% |
| 5 y5 years | +1311.1% | -1.0% |
ELVN Shareholders Equity Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +420.1% | -9.2% | +475.4% |
| 5 y | 5-year | at high | +420.1% | -9.2% | +475.4% |
| alltime | all time | at high | +420.1% | -9.2% | +475.4% |
Enliven Therapeutics Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $288.40 M(-5.4%) |
| Jun 2024 | - | $304.93 M(-4.0%) |
| Mar 2024 | - | $317.71 M(+29.2%) |
| Dec 2023 | $245.91 M | $245.91 M(-6.1%) |
| Sep 2023 | - | $261.75 M(-6.2%) |
| Jun 2023 | - | $278.99 M(-4.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $291.42 M(-479.3%) |
| Dec 2022 | -$76.83 M(+79.1%) | -$76.83 M(+12.8%) |
| Sep 2022 | - | -$68.10 M(+58.8%) |
| Dec 2021 | -$42.89 M(+111.2%) | - |
| Dec 2021 | - | -$42.89 M |
| Dec 2020 | -$20.30 M | - |
FAQ
- What is Enliven Therapeutics annual stockholders equity?
- What is the all time high annual shareholders equity for Enliven Therapeutics?
- What is Enliven Therapeutics annual shareholders equity year-on-year change?
- What is Enliven Therapeutics quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Enliven Therapeutics?
- What is Enliven Therapeutics quarterly shareholders equity year-on-year change?
What is Enliven Therapeutics annual stockholders equity?
The current annual shareholders equity of ELVN is $245.91 M
What is the all time high annual shareholders equity for Enliven Therapeutics?
Enliven Therapeutics all-time high annual stockholders equity is $245.91 M
What is Enliven Therapeutics annual shareholders equity year-on-year change?
Over the past year, ELVN annual stockholders equity has changed by +$322.73 M (+420.09%)
What is Enliven Therapeutics quarterly stockholders equity?
The current quarterly shareholders equity of ELVN is $288.40 M
What is the all time high quarterly shareholders equity for Enliven Therapeutics?
Enliven Therapeutics all-time high quarterly stockholders equity is $317.71 M
What is Enliven Therapeutics quarterly shareholders equity year-on-year change?
Over the past year, ELVN quarterly stockholders equity has changed by -$29.31 M (-9.23%)